Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, 90245, Indonesia.
Department of Biochemistry, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University of Malang, Batu, East Java, 65151, Indonesia.
Med Clin (Barc). 2020 Aug 28;155(4):143-151. doi: 10.1016/j.medcli.2020.05.017. Epub 2020 Jun 5.
Common laboratory parameters are crucial in aiding coronavirus disease 2019 (COVID-19) case detection. This study aimed to determine the differences between laboratory parameters in (1) COVID-19 versus non-COVID-19 pneumonia, and (2) severe versus non-severe COVID-19 cases.
Studies were collected until March 2020, and retrieved parameters include leukocyte, neutrophil, thrombocyte, and lymphocyte counts in addition to C-reactive protein (CRP), procalcitonin (PCT) and D-dimer levels. In the presence of heterogeneity, the random-effect model (REM) was used instead of the fixed-effect model (FEM).
Seven studies in the first analysis showed significantly lower leukocyte, neutrophil and platelet counts in COVID-19 pneumonia (SMD=-0.42, 95%CI -0.60 to -0.25, p<0.00001, SMD=-0.23, 95%CI -0.41 to -0.06, p=0.01, SMD=-0.54, 95%CI -0.91 to -0.16, p=0.0005) compared to non-COVID-19 pneumonia. Twenty-six studies in the second analysis showed significantly lower lymphocyte and thrombocyte counts (SMD=-0.56, 95%CI -0.71 to -0.40, p<0.0001, SMD=-0.32, 95%CI -0.49 to -0.15, p=0.0002) and significantly higher leukocyte, neutrophil, D-dimer, and CRP (SMD=0.31, 95%CI 0.07-0.56, p=0.01; SMD=0.44, 95%CI 0.24-0.64, p<0.0001; SMD=0.53, 95%CI 0.31-0.75, p<0.00001; SMD=0.97, 95%CI 0.70-1.24, p<0.00001) in severe COVID-19 compared to non-severe COVID-19.
In conclusion, thrombocyte count is key in both diagnosis and prognosis. Low leukocyte and neutrophil counts are markers of COVID-19 infection, but contrastingly higher counts indicate progressive COVID-19. And although lymphocyte, D-dimer and CRP levels did not demonstrate diagnostic value, all indicate severity of COVID-19. Confirmation of these findings should be performed in future studies.
在辅助 2019 年冠状病毒病(COVID-19)病例检测中,常规实验室参数至关重要。本研究旨在确定(1)COVID-19 与非 COVID-19 肺炎,以及(2)重症与非重症 COVID-19 病例之间实验室参数的差异。
研究收集截至 2020 年 3 月,检索的参数包括白细胞、中性粒细胞、血小板和淋巴细胞计数,以及 C 反应蛋白(CRP)、降钙素原(PCT)和 D-二聚体水平。在存在异质性的情况下,使用随机效应模型(REM)代替固定效应模型(FEM)。
第一项分析中的 7 项研究表明,COVID-19 肺炎患者的白细胞、中性粒细胞和血小板计数明显较低(SMD=-0.42,95%CI-0.60 至-0.25,p<0.00001,SMD=-0.23,95%CI-0.41 至-0.06,p=0.01,SMD=-0.54,95%CI-0.91 至-0.16,p=0.0005),而非 COVID-19 肺炎。第二项分析中的 26 项研究表明,淋巴细胞和血小板计数明显较低(SMD=-0.56,95%CI-0.71 至-0.40,p<0.0001,SMD=-0.32,95%CI-0.49 至-0.15,p=0.0002),白细胞、中性粒细胞、D-二聚体和 CRP 明显较高(SMD=0.31,95%CI 0.07-0.56,p=0.01;SMD=0.44,95%CI 0.24-0.64,p<0.0001;SMD=0.53,95%CI 0.31-0.75,p<0.00001;SMD=0.97,95%CI 0.70-1.24,p<0.00001),重症 COVID-19 患者较非重症 COVID-19 患者更为明显。
总之,血小板计数在诊断和预后中均为关键指标。白细胞和中性粒细胞计数较低是 COVID-19 感染的标志物,但相反,较高的计数则表明 COVID-19 呈进展性。虽然淋巴细胞、D-二聚体和 CRP 水平无诊断价值,但均表明 COVID-19 病情严重。应在未来的研究中对这些发现进行确认。